Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionLarson Financial Group LLC
Latest Disclosed Ownership1,542 shares
Latest Disclosed Value $ 203,143
Larson Financial Group LLC reports 53.43% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Larson Financial Group LLC filed a 13F-HR form disclosing ownership of 1,542 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $203,143 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 1,005 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 53.43% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,542 537 53.43 203 42.96 0.0061
2026-02-06 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,005 248 32.76 143 33.96 0.0047
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 757 47 6.62 106 19.10 0.0037
2025-08-08 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 710 310 77.50 89 102.27 0.0036
2025-05-02 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 400 -1,013 -71.69 44 -77.08 0.0021
2025-02-07 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,413 12 0.86 193 19.25 0.0100
2024-11-12 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,401 -492 -25.99 161 -38.08 0.0092
2024-08-02 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,893 -320 -14.46 261 -14.75 0.0178
2024-05-03 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,213 -44 -1.95 305 2.69 0.0236
2024-02-01 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,257 2,246 20,418.18 297 29,600.00 0.0260
2023-11-03 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11 11 1 0.0001
2023-05-04 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,331 -100.00 0 -100.00
2023-02-03 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,331 391 20.15 278 34.95 0.0333
2022-11-03 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,940 122 6.71 206 16.38 0.0293
2022-08-04 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,818 1,818 177 0.0306
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.